Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Clinical trial NCT00206726 · COMPLETED

Trial details

NCT number: NCT00206726
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell

Start date: 2005-05-01
Primary completion: 2008-04-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.